CKDXF (Ceryvyn Therapeutics) YoY EBITDA Growth: 96.03% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Ceryvyn Therapeutics YoY EBITDA Growth?

Ceryvyn Therapeutics CKDXF YoY EBITDA Growth is 96.03% as of Jun. 2025. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Ceryvyn Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2025 was 96.03%.

Ceryvyn Therapeutics's EBITDA per Share for the six months ended in Jun. 2025 was $-0.01.

Ceryvyn Therapeutics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics YoY EBITDA Growth Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -142.86 -107.35 -8.16 -2.30 67.63

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.90 -9.40 3.82 41.72 96.03

Ceryvyn Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Ceryvyn Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.101--0.312)/ | -0.312 |
=67.63 %

Ceryvyn Therapeutics's YoY EBITDA Growth for the quarter that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (Q: Jun. 2025 )
=(EBITDA per Share (Q: Jun. 2025 )-EBITDA per Share (Q: Jun. 2024 )) / | EBITDA per Share (Q: Jun. 2024 )) |
=(-0.006--0.151)/ | -0.151 |
=96.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 96.03% mean?
Ceryvyn Therapeutics (CKDXF) has a YoY EBITDA Growth of 96.03% as of Jun. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' YoY EBITDA Growth too high?
Ceryvyn Therapeutics' current YoY EBITDA Growth is 96.03%.
How does Ceryvyn Therapeutics' YoY EBITDA Growth compare to VRTX and REGN?
Ceryvyn Therapeutics' YoY EBITDA Growth of 96.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current YoY EBITDA Growth is 96.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current YoY EBITDA Growth of 96.03%. The current YoY EBITDA Growth is 96.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current YoY EBITDA Growth is 96.03% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.